Duorui Pharmaceutical won the head of the local anesthetics national exclusive agent: enrich the product structure to create new profit growth points

It is understood that ropivacaine hydrochloride sodium chloride injection is mainly used for surgical operations, painless delivery and so on. Benefiting from the expansion of the anesthesia market demand, for Duorui Pharmaceutical, this cooperation will help the company to enter the anesthesia drug market, improve the business layout in the surgical field, and also enrich the company's product line and bring new profit growth points.

Take the head of the local anesthetic national exclusive agent

The agent sales business of Duorui Pharmaceutical is next to the next city.

Recently, Duorui Pharmaceutical signed the "Entrusted Sales Agreement" with Jinan Kangqiao. Jinan Kangqiao agreed that the company was exclusively entrusted to sell ropivacaine hydrochloride sodium chloride injection (0.2g: 100ml) nationwide and provided a letter of authorization. The entrustment period is from the date of signing of the agreement to December 31, 2026. After the expiration of the period, Jinan Kangqiao retains the priority right of the company to continue to sell the product exclusively throughout the country according to the sales situation.

Ropivacaine hydrochloride sodium chloride injection is one of the mainstream drugs at present, with the dual effects of anesthesia and analgesia, and can produce surgical anesthesia in large doses and sensory block (analgesia) in small doses with only limited non-progressive motor nerve block. In the current field of anesthesia, ropivacaine occupies the largest market share and is currently the leading drug of local anesthetics.

It is understood that duorui pharmaceutical agent ropivacaine hydrochloride sodium chloride injection is produced by Shandong Huaxin Pharmaceutical, which has created two national firsts.

On February 26, 2020, Shandong CEFC Pharmaceutical was approved for marketing according to the new category 4 declaration of ropivacaine hydrochloride sodium chloride injection, which is regarded as passing the consistency evaluation. At present, there is only 1 enterprise in Huaren Pharmaceutical co., Ltd. that produces and sells ropivacaine hydrochloride injection in China, and only 1 manufacturer in Shandong Huaxin Pharmaceutical that is declared to produce according to the new 4 categories.

At the same time, the holder of the marketing authorization for the product is Jinan Kangqiao, which is also the first injection registration approval held by a research and development enterprise in China. Up to now, Jinan Kangqiao, as the holder of the listing authorization, is the only enterprise that has declared and been approved in accordance with the Announcement on the Issuance of the Work Plan for the Reform of the Registration and Classification of Chemical Drugs, and no other enterprises have declared the product.

Cut into the anesthesia drug market and improve the business layout in the surgical field

Since its inception, Duorui Pharmaceutical has been deeply involved in the field of perioperative period and emergency rescue, and the conclusion of the exclusive agency agreement of Duorui Pharmaceutical will help it enter the anesthesia drug market and further improve its layout in the field of surgery.

Founded in 2016, the company is mainly engaged in the research and development, production and sales of chemical preparations and their APIs, and focuses on the product pipeline layout around the perioperative and emergency rescue fields, and has become a leading enterprise in the field of plasma substitute segmentation.

Ropivacaine hydrochloride sodium chloride injection is clinically mainly used for surgical anesthesia, acute pain control, continuous epidural infusion or intermittent single medication, and can be used for caesarean section, delivery analgesia, regional block, etc., and is the mainstream local anesthetic.

With the increase in the amount of surgery and the expansion of the scope of painless operation, in the past 20 years, China's anesthesia industry has expanded from 2 billion yuan to more than 23 billion yuan with the growth of anesthesia disciplines. Because of the high policy and technical barriers in the field of anesthetics, it is difficult for new products to change the existing pattern.

Duorui Pharmaceutical cooperated with well-known domestic pharmaceutical companies to win the national exclusive agent of head local anesthetic drugs, which will help it cut into the anesthesia drug market and deepen the company's layout in the field of surgical period and emergency rescue.

Enrich the product structure and create new profit growth points

The main source of income of Duorui Pharmaceutical is the first generic drug in China, sodium acetate Ringer Injection, which was launched through independent research and development, and the company also admitted in the prospectus that the company's product structure needs to be further enriched. This cooperation is also expected to achieve this goal.

It is understood that the core drug of Duorui Pharmaceutical is sodium acetate Ringer injection, which mainly corrects acidosis, and the clinical application departments include anesthesiology, ICU, emergency department, major surgery, burn department, etc. From 2018 to 2020, it contributed more than 90% of the current main business income to the company.

In recent years, the anesthetic market has continued to grow, and the application of anesthetic drugs in ICU, obstetrics and gynecology, orthopedics, surgery and other departments has gradually been promoted, and the industry scale is expected to further grow rapidly.

Taking obstetrics and gynecology as an example, Huang Weijian, anesthesiologist at Guangdong Provincial Maternal and Child Health Hospital, said in an interview with 21st Century Business Herald that the most authoritative local anesthetic for childbirth is now ropivacaine. Because the mother must reduce the pain after the anesthetic, but also can not let the mother's contractions and lower limb muscle strength be affected, ropivacaine will have a role in separating movement and sensation. Most of the local anesthetics for childbirth in most hospitals are now replaced with ropivacaine.

Benefiting from the increased demand for surgical volumes, the expansion of applications in non-surgical departments such as ICU and obstetrics and gynecology, especially with the popularity of painless delivery, the market demand for ropivacaine is expected to further expand. Relevant agencies estimate that with the current compound growth rate of about 8%, by 2023, the total market size of China's anesthesia industry will reach 34.21 billion yuan.

It is conceivable that the agent head anesthetic drug will also be expected to enrich the product layout of Duorui Pharmaceutical and bring new profit growth points.